Drugs / TolDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01352858 | Feb 2012 → Nov 2018 | rheumatoid arthritis | Newcastle University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tolDC | “Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.” NCT01352858 ↗ |
| Known as | tolerogenic dendritic cells | “Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.” NCT01352858 ↗ |
| Modality | Cell therapy | “Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.” PMID 27117700 ↗ Apr 2016 |
| Route | Other | “intra-articular (IA) autologous tolerogenic dendritic cells” PMID 27117700 ↗ Apr 2016 |